Hospital admissions for idiopathic inflammatory myopathies have more than doubled over 28 years, with the rise limited to ...

Adding irinotecan to adjuvant oxaliplatin-based chemotherapy does not improve 3-year disease-free survival in patients with ...

More than one quarter of parents have knowingly misrepresented their child’s symptoms to get physicians to write a prescription for antibiotics, a new study in JAMA Network Open found.

Patients with head and neck cancer who attended a survivorship clinic before completing RT were more likely to complete treatment on schedule and had better 3-year DFS than those who did not attend.

Retinal photographs of recreational athletes reveal that active anabolic steroid users have less branching in the eye’s small ...

With GLP-1 receptor agonist (GLP-1 RAs) use on the rise in reproductive age women, the American College of Obstetricians and Gynecologists (ACOG) has released new guidance on a growing challenge in ...

In the head-to-head TRANSCEND-T2D-2 trial, participants with type 2 diabetes (T2D) lost more than twice as much weight with retatrutide as with Ozempic (semaglutide) and had a greater reduction in A1c ...

In a phase 2b trial, naronapride, an investigational dual-action prokinetic, administered at 20 or 40 mg three times daily for 12 weeks led to significantly greater improvement in core symptoms than ...

A patient started on a once-daily inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) inhaler for COPD and a patient started on that same class of inhaler ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

In COPD, two single-inhaler triple therapies have trial-based mortality findings that neither current US label includes as an efficacy claim. Trelegy Ellipta ...

A patient newly diagnosed with low-symptom COPD and a patient with severe, poorly controlled asthma despite inhaled corticosteroids and a long-acting beta-agonist (LABA) may both end up on a ...